Recombinant Human F7/Coagulation factor VII Protein, N-His

Description of Recombinant Human F7/Coagulation factor VII Protein, N-His

Introduction to Recombinant Human F7/Coagulation Factor VII Protein

Recombinant Human F7/Coagulation Factor VII Protein, also known as coagulation factor VIIa, is a protein that plays a crucial role in the blood clotting process. It is a recombinant protein, meaning it is produced through genetic engineering techniques, and is identical to the naturally occurring human form of the protein. This protein has a complex structure and functions as a key component in the coagulation cascade, making it an essential therapeutic agent for treating bleeding disorders.

Structure of Recombinant Human F7/Coagulation Factor VII Protein

The structure of Recombinant Human F7/Coagulation Factor VII Protein is composed of 406 amino acids, with a molecular weight of approximately 50 kDa. It is a single-chain glycoprotein, meaning it contains both carbohydrate and protein components. The protein has a globular shape with two domains: a light chain and a heavy chain. The light chain contains the active site, responsible for the protein’s coagulation activity, while the heavy chain contains the binding site for tissue factor, a key component in the coagulation process.

The carbohydrate component of the protein is essential for its stability and function. It consists of five N-linked glycosylation sites, which are crucial for maintaining the protein’s structure and activity. Additionally, the presence of terminal sialic acid residues on the carbohydrate component has been shown to enhance the protein’s half-life in the bloodstream.

Activity of Recombinant Human F7/Coagulation Factor VII Protein

Recombinant Human F7/Coagulation Factor VII Protein is a potent coagulation factor that plays a vital role in the formation of blood clots. It works by activating other coagulation factors, leading to the conversion of fibrinogen to fibrin, the main component of blood clots. This process is essential for stopping bleeding and promoting wound healing.

One of the unique features of Recombinant Human F7/Coagulation Factor VII Protein is its ability to bind to tissue factor, a protein found on the surface of cells that is exposed during tissue damage. This binding enhances the protein’s activity and allows it to initiate the coagulation process more efficiently. Additionally, the protein has been shown to have a longer half-life compared to other coagulation factors, making it an effective treatment option for bleeding disorders.

Application of Recombinant Human F7/Coagulation Factor VII Protein

Recombinant Human F7/Coagulation Factor VII Protein has a wide range of applications, primarily in the treatment of bleeding disorders. It is used to treat patients with hemophilia A or B, a genetic disorder where the blood does not clot properly due to a deficiency in coagulation factors. The protein is also used to treat patients with acquired hemophilia, a rare autoimmune disorder where the body produces antibodies that attack and inhibit coagulation factors.

Furthermore, Recombinant Human F7/Coagulation Factor VII Protein is used in surgical procedures to control bleeding in patients with coagulation disorders or those undergoing anticoagulant therapy. It has also been explored as a potential treatment for other conditions, such as traumatic brain injury, where excessive bleeding can be life-threatening.

Conclusion

Recombinant Human F7/Coagulation Factor VII Protein is a crucial therapeutic agent for treating bleeding disorders. Its complex structure and potent coagulation activity make it an effective treatment option for patients with hemophilia and other coagulation disorders. With ongoing research and advancements in genetic engineering techniques, this protein holds great potential for further applications in the field of medicine.